Most Read Articles
Elaine Soliven, 3 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
Stephen Padilla, 4 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 3 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.

Low cholesterol may be detrimental to older men not taking statins

05 Nov 2019

Low total cholesterol levels appear to carry increased major adverse cardiovascular events (MACE) hazard in older men without ischaemic heart disease (IHD) and not receiving statin therapy but not to those on statins, according to data from the CHAMP (Concord Health and Ageing in Men Project) cohort.

Researchers followed 1,298 community-dwelling men (mean age, 77 years) for a mean of 6.4 years. Of the participants, 558 were on statin therapy, with atorvastatin (45.9 percent) being the most commonly used, followed by simvastatin (44.3 percent), pravastatin (9.7 percent) and rosuvastatin (0.2 percent).

Most statin users (41.2 percent) were on moderate-intensity doses, while 34.8 percent were on low-intensity and 24.0 percent were on high-intensity doses. Furthermore, participants on statin therapy had lower total cholesterol (TC), low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol levels compared with those not taking statins.

Men with lower TC had higher rates of MACE, mortality, myocardial infarction and congestive cardiac failure. In Cox regression models, decreasing TC level correlated with increased comorbidity burden, frailty and MACE (p-linear trend<0.001).

Among participants not taking statins (n=731), each 1-mmol/L decrease in TC was associated with about a 30-percent increased risk of MACE (hazard ratio [HR], 1.27, 95 percent confidence interval [CI], 1.10–1.45; p=0.001) and mortality (HR, 1.22, 95 percent CI, 1.03–1.44; p=0.02).

Conversely, low TC in men on statins was associated with neither MACE risk (HR, 0.91, 95 percent CI, 0.74–1.11) nor mortality (HR, 0.86, 95 percent CI, 0.68–1.09).

The present data offer reassurance to men aged ≥70 years and taking statins that lower TC or LDL levels exert no unfavourable effect, but suggest that low cholesterol in those not on statins is a risk factor for adverse events.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elaine Soliven, 3 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
Stephen Padilla, 4 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 3 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.